Status:
UNKNOWN
Effect of Acute and Sub-acute Administration of Gluten on Extra-intestinal and Gastrointestinal Symptoms in Patients With Non-coeliac Gluten Sensitivity
Lead Sponsor:
Universitaire Ziekenhuizen KU Leuven
Conditions:
NCGS
Gluten
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
The investigators will investigate the effects of acute and sub-acute administration of gluten on mood, intestinal permeability, gastrointestinal symptoms, gut microbiota and cortisol levels in NCGS p...
Eligibility Criteria
Inclusion
- Non-coeliac gluten sensitivity patients
- Previous symptoms of IBS fulfilling Rome III criteria that self reportedly improved with a gluten-free diet
- Symptoms currently well controlled on a gluten-free diet
- Adherence to the gluten-free diet for at least 6 weeks prior to recruitment
- Coeliac disease excluded (either by absence of the HLA-DQ2 and HLA-DQ8 haplotype or by a normal duodenal biopsy (Marsh 0) performed at endoscopy while on a gluten-containing diet in individuals expressing the HLA-DQ2 or HLA-DQ8 haplotype)
- IgA anti-tissue-transglutaminase or IgG anti-deaminated gliadin peptide positive
- Body Mass Index (BMI) of 20 - 25 kg/m2
- Stable body weight for at least 3 months prior to the start of the study
Exclusion
- Medical
- Coeliac disease
- Abdominal or thoracic surgery. Exception: appendectomy
- Gastrointestinal, endocrine or neurological diseases
- Cardiovascular, respiratory, renal or urinary diseases
- Hypertension
- Food or drug allergies
- Psychiatric disorders
- Eating disorders
- Depressive disorders
- Anxiety disorders
- Psychotic disorders
- Restraint or emotional eating
- Medication on a regular basis, exception: oral contraception
- History of cannabis use or any other drug of abuse for at least 12 months prior to the study
- Alcohol abuse (more than 21 units of alcohol for men, more than 14 units for woman per week)
- Pregnant or breastfeeding women
Key Trial Info
Start Date :
May 11 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2022
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03798249
Start Date
May 11 2017
End Date
January 1 2022
Last Update
January 9 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
TARGID
Leuven, Vlaams-Brabant, Belgium
2
Jan Tack
Leuven, Belgium, 3000